MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaip.2025.07.046

Медицинская библиотека · The journal of allergy and clinical immunology. In practice · 2025

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.

Yang Xinyan, Wang Lihong, Huang Kewu, Tang Wei, Berame Eli John, Park Hae-Sim, Hunter Gillian, Jiang Wei, Wu Chengyi Chloe, Min Chiju Wendy, Domek-Zielinska Katarzyna, Lal Harbans, Molfino Nestor A, Ponnarambil Sandhia S, Zhong Nanshan

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Tezepelumab, a human monoclonal antibody that blocks thymic stromal lymphopoietin, reduced the annualized asthma exacerbation rate (AAER) and improved lung function, asthma control, and health-related quality of life (HRQoL) in patients with severe, uncontrolled asthma (SUA) in the global, phase 3 NAVIGATOR study (NCT03347279).

OBJECTIVE

DIRECTION was a phase 3, multicenter, double-blind study that assessed the efficacy and safety of tezepelumab in adults with SUA in China, the Philippines, and the Republic of Korea.

METHODS

Patients (18-80 years old) with SUA (no baseline biomarker restrictions) were randomized 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end point was the AAER over 52 weeks. Key secondary end points were changes from baseline to week 52 in prebronchodilator forced expiratory volume in 1 second (FEV1) and Asthma Control Questionnaire-6 (ACQ-6), Asthma Quality of Life Questionnaire (standardized) for patients 12 years and older (AQLQ[S]+12), and Asthma Symptom Diary (ASD) scores. Safety was also assessed.

RESULTS

Overall, 400 patients received tezepelumab (n = 201) or placebo (n = 199). Tezepelumab significantly reduced AAERs versus placebo by 74% (95% confidence interval [CI]: 61, 83; P < .001) in the overall population and by 60% (95% CI: 31, 77) in patients with baseline blood eosinophil count <300 cells/μL. Tezepelumab significantly improved prebronchodilator FEV1 (least-squares mean difference: 0.24 L [95% CI: 0.16, 0.32]) and ACQ-6, AQLQ(S)+12, and ASD scores at week 52 versus placebo (all P ≤ .001). No new safety concerns were identified.

CONCLUSIONS

Tezepelumab reduced exacerbations and improved lung function, asthma control, and HRQoL in Asian patients with SUA, consistent with prior study findings.

Для цитирования: Yang Xinyan, Wang Lihong, Huang Kewu, Tang Wei, Berame Eli John, Park Hae-Sim, Hunter Gillian, Jiang Wei, Wu Chengyi Chloe, Min Chiju Wendy, Domek-Zielinska Katarzyna, Lal Harbans, Molfino Nestor A, Ponnarambil Sandhia S, Zhong Nanshan. Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.. The journal of allergy and clinical immunology. In practice. 2025. DOI: 10.1016/j.jaip.2025.07.046.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.